Alavi A

References (2)

Title : Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit - Hoilund-Carlsen_2024_Ageing.Res.Rev__102348
Author(s) : Hoilund-Carlsen PF , Alavi A , Barrio JR , Castellani RJ , Costa T , Herrup K , Kepp KP , Neve RL , Perry G , Revheim ME , Robakis NK , Sensi SL , Vissel B
Ref : Ageing Res Rev , :102348 , 2024
Abstract :
PubMedSearch : Hoilund-Carlsen_2024_Ageing.Res.Rev__102348
PubMedID: 38830549

Title : Clinical spectrum in multiple families with primary COQ(10) deficiency - Hashemi_2021_Am.J.Med.Genet.A_185_440
Author(s) : Hashemi SS , Zare-Abdollahi D , Bakhshandeh MK , Vafaee A , Abolhasani S , Inanloo Rahatloo K , DanaeeFard F , Farboodi N , Rohani M , Alavi A
Ref : American Journal of Medicine Genet A , 185 :440 , 2021
Abstract :
PubMedSearch : Hashemi_2021_Am.J.Med.Genet.A_185_440
PubMedID: 33215859